PP
TRDA icon

PDT Partners’s Entrada Therapeutics TRDA Stock Holding History

PDT Partners’s Portfolio TRDA Stock Details TRDA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-12,538
Closed -$217K – 856
2024
Q4 		$217K Sell
12,538
-100
-0.8% -$1.81K 0.02% 642
2024
Q3 		$202K Buy
12,638
+100
+0.8% +$1.58K 0.02% 659
2024
Q2 		$179K Sell
12,538
-15
-0.1% -$213 0.02% 620
2024
Q1 		$178K Buy
+12,553
New +$177K 0.02% 583

Other funds holding TRDA

BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
5VM
5AM Venture Management San Francisco, California $288M AUM 313.93% 1-Year Est. Return
MAM
MPM Asset Management Boston, Massachusetts $44.5M AUM 47.28% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
MC
Merck & Co Rahway, New Jersey $526M AUM 175.27% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

PDT Partners's TRDA Position: Q1 2025 in Review

PDT Partners sold out of Entrada Therapeutics (TRDA) in Q1 2025, closing a stake of 12,538 shares — an estimated $217K sold.

PDT Partners first reported a position in TRDA in Q1 2024 and held it in 4 quarters. The position peaked at $217K in Q4 2024. 111 funds tracked by Wall St. Rank hold TRDA as of Q1 2025.

  • PDT Partners reported no remaining Entrada Therapeutics position as of Q1 2025 after selling out during the quarter.
  • PDT Partners sold 12,538 Entrada Therapeutics shares in Q1 2025, an estimated $217K.
  • PDT Partners first reported a position in Entrada Therapeutics in Q1 2024 and held it in 4 quarters.
  • PDT Partners's Entrada Therapeutics position peaked at $217K in Q4 2024.
  • 111 funds tracked by Wall St. Rank held Entrada Therapeutics as of Q1 2025.

Based on PDT Partners's 13F filing for Q1 2025, filed 15 May 2025.